Frederic Triebel

Frederic Triebel

Company: Immutep

Job title: Chief Scientific Officer & Chief Medical Officer


A Soluble LAG-3 Protein (eftilagimod alpha) with an Anti-PD-1 Antibody (Pembrolizumab) Tested in Two phase II Studies in HNSCC 12:05 pm

An MHC class II agonist (eftilagimod) used as an antigen-presenting cell (APC) activator combined with an immune checkpoint inhibitor (ICI): a unique combination in immuno-oncology Results of the TACTI-002 (Two ACTive Immunotherapies) phase II trial in second-line PD-X naïve head and neck small cell carcinoma (HNSCC) patients Presentation of the ongoing TACTI-003 randomized phase IIb…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.